- Home
- EDRY vs NRXP Comparison
EDRY vs NRXP Comparison
Compare EDRY & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- NRXP
- Stock Information
- Founded
- EDRY 2018
- NRXP 2015
- Country
- EDRY Greece
- NRXP United States
- Employees
- EDRY 296
- NRXP N/A
- Industry
- EDRY Marine Transportation
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- NRXP Health Care
- Exchange
- EDRY Nasdaq
- NRXP Nasdaq
- Market Cap
- EDRY 24.6M
- NRXP 32.6M
- IPO Year
- EDRY N/A
- NRXP N/A
- Fundamental
- Price
- EDRY $8.83
- NRXP $2.03
- Analyst Decision
- EDRY
- NRXP Strong Buy
- Analyst Count
- EDRY 0
- NRXP 4
- Target Price
- EDRY N/A
- NRXP $28.25
- AVG Volume (30 Days)
- EDRY 4.2K
- NRXP 128.2K
- Earning Date
- EDRY 05-20-2025
- NRXP 05-13-2025
- Dividend Yield
- EDRY N/A
- NRXP N/A
- EPS Growth
- EDRY N/A
- NRXP N/A
- EPS
- EDRY N/A
- NRXP N/A
- Revenue
- EDRY $61,083,227.00
- NRXP N/A
- Revenue This Year
- EDRY N/A
- NRXP N/A
- Revenue Next Year
- EDRY $42.57
- NRXP N/A
- P/E Ratio
- EDRY N/A
- NRXP N/A
- Revenue Growth
- EDRY 28.35
- NRXP N/A
- 52 Week Low
- EDRY $8.00
- NRXP $1.10
- 52 Week High
- EDRY $24.84
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- EDRY 38.47
- NRXP 48.76
- Support Level
- EDRY $8.40
- NRXP $1.85
- Resistance Level
- EDRY $9.50
- NRXP $2.07
- Average True Range (ATR)
- EDRY 0.59
- NRXP 0.15
- MACD
- EDRY -0.02
- NRXP 0.03
- Stochastic Oscillator
- EDRY 30.52
- NRXP 71.43
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulks such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.